NODAGA-LM3

• UNSPSC Description:

  NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas[1][2].

• Target Antigen:

  Radionuclide-Drug Conjugates (RDCs); Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nodaga-lm3.html

• Purity:

  99.33

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@H](NC([C@@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@@H](C(N)=O)CC2=CC=C(C=C2)O)=O)NC([C@@H](NC(CCC(N3CCN(CCN(CC3)CC(O)=O)CC(O)=O)C(O)=O)=O)CC4=CC=C(C=C4)Cl)=O)=O)CC5=CC=C(C=C5)O)N[C@@H]1CC6=CC=C(C=C6)NC(N)=O

• Molecular Weight:

  1521.11

• References & Citations:

  [1]Fani M, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011 Jul;52(7):1110-8. |[2]Zhu W, et al. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021 Oct;62(10):1398-1405.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  Phase 2